Availability of 64 Cu-DOTATATE PET/CT for Neuroendocrine Tumours: A New Opportunity for Staging and PRRT Selection (EANM 2026) - Sep 29, 2026 - Abstract #EP-0422; "In two patients (18.2%), imaging findings modified therapeutic management, leading to initiation of 177Lu-DOTATATE therapy... 64Cu-DOTATATE PET/CT demonstrated clinically relevant diagnostic and therapeutic impact, detecting additional disease sites in a substantial proportion of patients and leading to treatment strategy modifications in selected cases. Its longer physical half-life compared with 68Ga improves tracer logistics, enables flexible and delayed imaging protocols, and enhances radiopharmaceutical availability. This represents a significant operational advantage, particularly for centers without on-site 68Ga generator infrastructure."
Lung Cancer • Neuroendocrine Tumor • Oncology • Solid Tumor • SSTR
|
|
M. Guiote Moreno 1, 2; A. De Agrela Serrao 1, 2; I. Cejudo Liebana 1, 2; J. Fernandez Fernandez 1, 2; A. Rodriguez Lllamas 1, 2; J. Vallejo Casas 1, 2
|